Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
NCT06975514

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

Led by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Updated on 2025-07-15

60

Participants Needed

16

Research Sites

22 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

CONDITIONS

Official Title

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females aged 18 to under 65 years.
  • Meet clinical diagnostic criteria for insomnia disorder (ICSD-3).
  • Sleep onset latency of 30 minutes or more for at least 3 nights per week and/or wake after sleep onset of 60 minutes or more for at least 3 nights per week within 4 weeks before screening.
  • Able to recognize 26 English letters and have no cognitive impairment based on MMSE score.
  • During run-in and Day 1 of treatment, sleep onset latency of 30 minutes or more for at least 3 nights in 7 days and/or wake after sleep onset of 60 minutes or more for at least 3 nights confirmed by sleep diary.
  • Polysomnography during run-in shows mean latency to persistent sleep of at least 30 minutes for 2 nights and/or mean wake after sleep onset of at least 60 minutes for 2 nights; sleep efficiency 85% or less for 2 nights.
  • Insomnia Severity Index (ISI) score of 15 or higher at screening and Day 1.
  • Bedtime between 9 p.m. and 1 a.m., wake time between 5 a.m. and 10 a.m., and in-bed time of 6.5 to 9 hours for at least 5 nights in last 7 days.
  • Agreement to use effective contraception from screening through 30 days after last dose, if of reproductive age.
  • Understand study procedures, voluntarily consent, and agree to attend study visits with good compliance.
Not Eligible

You will not qualify if you...

  • Allergy or hypersensitivity to YZJ-1139, zolpidem, or their ingredients.
  • Serious medical conditions affecting safety or study assessments, including endocrine, blood, heart, brain, gastrointestinal, liver, kidney, autoimmune, or respiratory diseases.
  • Insomnia caused by other physical conditions like chronic pain, eczema, or allergies.
  • History of psychiatric or neurological diseases such as epilepsy, schizophrenia, bipolar disorder, cognitive disorders, or other mental illnesses affecting safety or assessments.
  • Past or current sleep-related respiratory or movement disorders including sleep apnea, restless legs syndrome, narcolepsy, or periodic limb movement disorder.
  • History of complex sleep behaviors like sleep driving or sleep eating.
  • Nocturia caused by urinary or prostate issues.
  • Hyperthyroidism.
  • Recent history of alcohol abuse or excessive caffeine intake.
  • Smoking more than 10 cigarettes per day recently or inability to refrain from smoking.
  • Lifestyle factors interfering with study, such as travel across multiple time zones or shift work.
  • History of drug abuse or positive drug screening.
  • Use of certain medications affecting sleep within 1 week before run-in.
  • Planned surgery during study.
  • Depression or anxiety above defined severity thresholds.
  • Suicidal ideation or behavior within recent years.
  • Abnormal ECG or liver/kidney function tests.
  • HIV positive status.
  • Sleep study abnormalities above defined limits.
  • Recent vaccination.
  • Participation in other clinical trials recently.
  • Prior participation in YZJ-1139 trials or treatment with similar drugs with treatment failure.
  • Pregnant or breastfeeding women.
  • Any other conditions judged unsuitable by investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Peking University People's Hospital

Beijing, China

Actively Recruiting

2

ChengDu Second People's Hospital

Chengdu, China

Actively Recruiting

3

ChongQing Traditional Chinese Medicine Hospital

Chongqing, China

Actively Recruiting

4

Deyang People's Hospital

Deyang, China

Actively Recruiting

5

The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)

Guangzhou, China

Actively Recruiting

6

The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)

Jinan, China

Actively Recruiting

7

The Second Affiliated Hospital Of NanChang University

Nanchang, China

Actively Recruiting

8

The First Affiliated Hospital of Ningbo University

Ningbo, China

Actively Recruiting

9

ShengJing Hospital Of China Medical University

Shenyang, China

Actively Recruiting

10

The Third Hospital of Hebei Medical University

Shijiazhuang, China

Actively Recruiting

11

SuZhou GuangJi Hospital

Suzhou, China

Actively Recruiting

12

The Second Affiliated Hospital of Soochow University

Suzhou, China

Actively Recruiting

13

Tianjin Anding Hospital

Tianjin, China

Actively Recruiting

14

Wuhan No.1 Hospital

Wuhan, China

Actively Recruiting

15

Yan'an University Xianyang Hospital

Yan’an, China

Actively Recruiting

16

The Second Affiliated Hospital of Zhengzhou University

Zhengzhou, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here